Bitencourt et al. [126] used AI in conjunction with clinical variables to assess the complete pathologic response after neoadjuvant chemotherapy in overexpressing HER2 breast cancer and found that it was 83.9% accurate. The gene discussed is ERBB2; the disease is breast carcinoma.